HilleVax (HLVX) Stock Price, News & Analysis

Company Overview

HilleVax, Inc. is a clinical-stage biotechnology company focused on the development of broadly protective vaccines against enteric pathogens. The company leverages a proprietary O-antigen platform to generate multivalent vaccine candidates designed to elicit immunity to multiple strains of enterotoxigenic Escherichia coli (ETEC), Shigella and Vibrio cholerae. HilleVax’s lead candidate, HIL-214, is currently advancing through Phase I clinical trials to assess safety and immunogenicity in adult populations.

Founded as a spin-out from Hilleman Laboratories with support from philanthropic and industry partners, HilleVax has built a pipeline of product candidates aimed at addressing diseases that disproportionately impact low- and middle-income countries as well as travelers. In addition to HIL-214, the company is developing second-generation candidates for shigellosis and cholera, each leveraging the same O-antigen conjugation technology to streamline manufacturing and broaden strain coverage. Strategic collaborations and research partnerships underpin the company’s efforts to optimize vaccine formulations and accelerate global development.

Headquartered in Cambridge, Massachusetts, HilleVax conducts research and development activities in the United States while engaging with international public health agencies, academic institutions and non-governmental organizations to support clinical trial execution and eventual vaccine deployment. Led by CEO William J. Harty, the management team brings extensive experience in vaccine development, regulatory affairs and global commercialization planning. As a publicly listed entity on NASDAQ under the symbol HLVX, HilleVax is positioning itself to address unmet medical needs in enteric disease prevention on a global scale.

Key Stats

• Today's Range: $2.09 to $2.09
• 50-Day Range: $2.04 to $2.12
• 52-Week Range: $1.34 to $2.17
• Volume: N/A
• Average Volume: 838,767 shs
• Market Capitalization: $104.79 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.00
• Consensus Rating: Hold

HilleVax Stock Analysis - MarketRank™

HilleVax scored higher than 22% of companies evaluated by MarketBeat, and ranked 848th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Hold

Consensus Rating

HilleVax has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for HilleVax is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

HilleVax has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for HilleVax are expected to grow in the coming year, from ($2.64) to ($1.92) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of HilleVax is -1.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of HilleVax is -1.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

HilleVax has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.56% of the float of HilleVax has been sold short.

Short Interest Ratio / Days to Cover

HilleVax has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in HilleVax has recently increased by 47.03%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

HilleVax does not currently pay a dividend.

Dividend Growth

HilleVax does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.56% of the float of HilleVax has been sold short.

Short Interest Ratio / Days to Cover

HilleVax has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in HilleVax has recently increased by 47.03%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

5 people have searched for HLVX on MarketBeat in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, HilleVax insiders have not sold or bought any company stock.

Percentage Held by Insiders

24.90% of the stock of HilleVax is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

86.42% of the stock of HilleVax is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

HLVX Stock Analysis - Frequently Asked Questions

How have HLVX shares performed this year?

HilleVax's stock was trading at $2.07 on January 1st, 2025. Since then, HLVX shares have increased by 1.0% and is now trading at $2.09.

How were HilleVax's earnings last quarter?

HilleVax, Inc. (NASDAQ:HLVX) posted its quarterly earnings results on Wednesday, August, 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.03.

When did HilleVax IPO?

HilleVax (HLVX) raised $200 million in an initial public offering on Friday, April 29th 2022. The company issued 11,765,000 shares at a price of $16.00-$18.00 per share.

How do I buy shares of HilleVax?

Shares of HLVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of HilleVax own?

Based on aggregate information from My MarketBeat watchlists, some other companies that HilleVax investors own include JPMorgan Chase & Co. (JPM), Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META) and Home Depot (HD).

Company Calendar

• Last Earnings: 8/06/2025
• Today: 10/08/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:HLVX
• CIK: 1888012
• Web: www.hillevax.com
• Phone: 617-213-5054
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for HilleVax: $2.00
• High Price Target: $2.00
• Low Price Target: $2.00
• Potential Upside/Downside: -4.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.43)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$147.27 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -34.29%
• Return on Assets: -28.50%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 26.39
• Quick Ratio: 26.39

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.10 per share
• Price / Book: 0.67

Miscellaneous

• Outstanding Shares: 50,140,000
• Free Float: 37,656,000
• Market Cap: $104.79 million
• Optionable: Not Optionable
• Beta: 0.77